



Fresenius Medical Care

P R E S S R E L E A S E

January 11, 2008
Bernd Ebeling
Corporate Communications
Tel.: +49-6172-6082378
Fax: +49-6172-6082294
e-mail: pr@fmc-ag.com
www.fmc-ag.com

Fresenius Medical Care Selected To Provide Dialysis Care to More than 400 Patients in the U.K.

Bad Homburg, Germany – Fresenius Medical Care AG & Co. KGaA (“the Company”) today announced that it has been selected by the National Health System (NHS) in the United Kingdom to manage dialysis care for 12 renal units across the North of England.

These clinics will provide dialysis treatments for more than 400 patients for approximately 7 years in North East and South Yorkshire and Lincolnshire. Patients will remain under the care of their NHS physicians, while benefiting from Fresenius Medical Care’s dedication, proven experience and expertise in hemodialysis.

This pioneering program – part of the British Government’s involvement in independent sector partnerships to deliver more choice and faster treatment to NHS patients – will see new renal dialysis units developed and existing hospital facilities extended. While new satellite centers will open the door to more patients and increase capacity, investment will also result in the installation of state-of-the art equipment and the latest technology, as well as the staff training and education.

Dr. Emanuele Gatti, Chief Executive Officer for the regions Europe, Middle East and Africa, commented: “We are very honored that Fresenius Medical Care has been chosen to work in partnership with the NHS to manage this innovative renal services program in the United Kingdom. We now have an outstanding opportunity to improve capacity for hemodialysis patients in the UK and provide easier access to services. Patients and the healthcare system at large can clearly benefit from our global expertise in renal care and our fully vertically integrated business model.”

According to Kidney Research UK, a charity funding research that focuses on kidney disease, between 600 to 800 patients per one million population need renal replacement therapy in form of dialysis or transplant for survival. Kidney Research expects the number of end-stage renal disease (ESRD) patients to increase by about 5% annually.

###

The Company’s subsidiary Fresenius Medical Care Renal Services UK is the leading provider of dialysis services to the NHS in the UK, operating 41 partnership dialysis units that provide chronic dialysis treatment for about 2,800 NHS patients.

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,221 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 172,227 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including uncertainties in the development of the home dialysis market, the ability to develop and commercialize technological innovations, changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.